Pharmacokinetics and Clinical Effectiveness of Methylphenidate

@article{Kimko1999PharmacokineticsAC,
  title={Pharmacokinetics and Clinical Effectiveness of Methylphenidate},
  author={Hui C. Kimko and James T. Cross and Darrell R. Abernethy},
  journal={Clinical Pharmacokinetics},
  year={1999},
  volume={37},
  pages={457-470}
}
Methylphenidate is prescribed for over 90% of children in the US diagnosed as having attention-deficit hyperactivity disorder (ADHD). Although ADHD has been widely studied, the use of methylphenidate in ADHD still poses a number of unresolved questions, including its pharmacodynamic characteristics (drug concentration-effect relationship) and the effect of long term treatment on the patient’s psychopathology later in life. The objective of this review is to provide an analysis of the… 
Pharmacokinetic Considerations in the Treatment of Attention-Deficit Hyperactivity Disorder with Methylphenidate
TLDR
The difficulties in administering methylphenidate multiple times a day, particularly during the school day, have been alleviated in the past few years by the development of extended-release preparations with varying behavioural effects lasting 8–12 hours.
Methylphenidate (OROS® Formulation)
TLDR
Once daily OROS® methylphenidate 18 to 54mg was significantly more effective than placebo and demonstrated an effect similar to IR methyl phenidate 5 to 15mg 3 times daily in reducing the symptoms of ADHD.
[Drug-induced psychosis after intake of a modified--release formulation of methylphenidate].
TLDR
It is concluded that the ingestion of an unintended overdose ofmethylphenidate may have caused the boy's psychotic symptoms and that routine therapeutic serum concentrations of methylphenidate have to be correlated to the point of time when the blood was drawn in relation to the intake ofethylphenidate.
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations
TLDR
Since there are no reliable biomarkers that can predict individualized response to long-acting stimulants, clinicians need to consider their distinctive pharmacokinetic properties, including the pharmacokinetics profile, rate and extent of absorption, variability, dose proportionality, bioequivalence and potential for accumulation.
Extended- Release Methylphenidate (Ritalin® LA)
TLDR
Extended-release methylphenidate improved both inattention and hyperactivity symptoms and was effective in children with combined- (inattentive and hyperactive/impulsive) type or predominantly inattentively-type ADHD.
Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage
TLDR
Weight is a reliable clinical parameter for optimal dose titration in patients with well-adjusted MPH treatment for ADHD and might be used for individual dose optimization and for monitoring of the prescribed dose.
Methylphenidate Controlled-Delivery Capsules (Equasym™XL, Metadate CD™)
TLDR
Methylphenidate CD resulted in superior control of ADHD symptoms compared with osmotic release oral system (OROS®) methylphenidate over a time period corresponding to that of an average school day in a laboratory classroom, in 3-week clinical trials conducted in a community setting.
Effectiveness and Tolerability of Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder
TLDR
Methylphenidate is a central nervous system stimulant, whose mechanism of action is thought to be due to an increase in catecholamines in areas of the brain concerned with motivation and reward, which is generally well tolerated and liked by children and adolescents with ADHD.
Single-Dose Pharmacokinetics of NWP06, an Extended-Release Methylphenidate Suspension, in Children and Adolescents with ADHD
TLDR
NWP06 was well tolerated with no serious adverse events and no adverse event-related treatment discontinuations, and there were no age-related pharmacokinetic differences after oral administration of NWP06 to children or adolescents in this small sample.
Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management
The prevalence of attention-deficit hyperactivity disorder (ADHD) in the USA is estimated at approximately 4–9 % in children and 4 % in adults. It is estimated that prescriptions for ADHD medications
...
...

References

SHOWING 1-10 OF 72 REFERENCES
Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder.
TLDR
The purpose of this present investigation was to determine whether the levels of methylphenidate were sustained for over a time period of 8 h, and to examine enantioselective aspects of the pharmacokinetics following the ingestion of the sustained-release formulation.
Pharmacokinetics of methylphenidate in hyperkinetic children.
TLDR
The brief half life ofethylphenidate which parallels the short duration of action of methylphenidate in behaviorally disordered children may be explained in part by its low protein binding which results in high percentage of free drug being made available for metabolism to pharmacologically inactive metabolites.
Clinical studies of methylphenidate serum levels in children and adults.
TLDR
Progress is reported on the progress in applying a reliable and sensitive gas chromatography-mass spectrometric assay for MPH in serum to clinical studies of hyperactive children and adults.
Sustained release methylphenidate: pharmacokinetic studies in ADDH males.
TLDR
Comparisons of the two sets of plasma concentration curves suggest that MPH-SR has a longer Tmax, but that it does not reach the same Cmax as an identical dose of standard MPH.
Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder.
TLDR
Methylphenidate has short-term positive effects on children and adolescents with CD and key aspects of antisocial adjustment appear to be treatment responsive, independent of severity of the children's initial ADHD symptoms.
Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children.
TLDR
Whereas overt behavior improved with increasing dose, academic functioning was improved with methylphenidate, but did not vary with either dose or task complexity, while Behavioral and academic improvements produced by a dose of 0.3 mg/kg in the morning were no longer evident in the afternoon, but a morning dose produced behavioral improvements that were clinically and statistically discernible in thenoon.
Enantioselective pharmacokinetics and pharmacodynamics of dl‐thero‐mcthylphenidate in children with attention deficit hyperactivity disorder
TLDR
The computer tests revealed a drug‐induced improvement in sustained attention that was entirely attributable to the d‐enantiomer, and there was no evidence to suggest that the effectiveness of d‐methylphenidate was in any way compromised by the presence of its antipode.
Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats.
TLDR
The results suggest that the dose-dependent characteristics of the MPD enantiomers may be due to the saturation in the presystemic elimination of the drug.
Pharmacokinetics of methylphenidate in man, rat and monkey.
TLDR
The pharmacokinetics and bioavailability of methylphenidate (MPH) and a metabolite, ritalinic acid (RA), were studied in normal adults, children with hyperactivity, monkeys and rats, suggesting substantial presystemic elimination of MPH.
Effects of methylphenidate dosage in hyperactive reading-disabled children: I. Behavior and cognitive performance effects.
TLDR
Hyperactive behaviors were significantly reduced in the 0.7 mg/kg dose group as compared with the placebo group, and teachers perceived an increase in hyperactivity during the last 3 months of treatment, and this was not explained by changes in methylphenidate plasma concentration.
...
...